Evidence gap
A values / turf tradeoff — more data alone will not resolve it.
Resolves via: Shared decision-making + role clarity
Get this wrong and patients with no symptoms get a valve they didn't need yet — or wait until the heart is already damaged.
Active since Jan 2024
The debate
25 clinicians quoted on the record
Waiting for symptoms risks irreversible heart damage and sudden death, and trials show early valve replacement cuts later hospitalizations and unplanned procedures with no clear downside.
“Early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization.”
“Aligning TAVR coverage with approved FDA indications, including asymptomatic AS”
+ 4 more on this side
The trials leaned on soft endpoints, skipped a surgery comparison arm, and we still don't know how these valves hold up over decades — so committing a symptom-free patient to a valve is premature.
“The EARLY TAVR trial does not establish a meaningful patient-centered benefit for asymptomatic Medicare beneficiaries”
“There was hope among some members of the community that we would come up with a level I recommendation for asymptomatic aortic stenosis, and we just didn’t feel that the evidence was clear enough.”
+ 1 more on this side
Where the experts land
6–3 on record · 16 unplaced
Fix it early · 6
On the record, unplaced · 16
Watch and wait · 3
“Aligning TAVR coverage with approved FDA indications, including asymptomatic AS”
Where the field stands
Common ground
Severe aortic stenosis eventually needs valve replacement, and acting early reduces hospital stays and strokes.
The crux
Is avoiding future hospital stays enough reason to replace the valve in a patient who feels well, when early TAVR has not been shown to extend life?
Still unknown
Longer follow-up showing whether early replacement improves survival, a head-to-head comparison with early surgery, and long-term durability data in younger patients would settle it.
On the record
Their own words — position stated as published
watchful waiting
“An asymptomatic person is really hard to make much better. If the patient is not complaining of anything, I think the evidentiary bar has to be quite high.”
John M. Mandrola · Electrophysiologist · 8 statements · Medscape ↗
do not use confounded registries to justify early TAVR
“Registry study showed 50% increase in mortality at 3y with delayed TAVR, but mortality was not increased in EARLY-TAVR at median f/u of 3.8y (HR 0.93, 0.60-1.44). Should we chase potentially confounded data to justify early TAVR?”
Sanjay Kaul · Cardiologist · 2 statements · X ↗
offer early TAVR, not mandate it
“I don't think we can say this is a level 1 recommendation. I think level 1 is a bridge too far.”
David J. Cohen · Director of clinical and outcomes research · Medscape ↗
IIa opens the door, cautiously
“this recommendation clearly opens the door for early treatment in, I think, a balanced and nice way.”
Fabien Praz · ESC chair · TCTMD ↗
Where do you land?
No votes yet — the measured split appears at 10.
Where the evidence stands
PROGRESS, presented at TCT 2026, reported upfront TAVR reduced death or HF events versus surveillance at 2 years in moderate AS with risk features. This extends the EARLY TAVR logic downstream of current guideline thresholds. Long-term durability, pacemaker risk, and whether “clinically significant AS” should replace the moderate/severe dichotomy are unsettled; 10-year follow-up is planned.
What's settled
4What's still open
4How this gets settled
A values / turf tradeoff — more data alone will not resolve it.
Who could settle it
Know an expert who could settle this? Suggest one →
Who could fund or run it
Institutions that could fund, run, or adopt
Sources & verification
+ 59 more, each dated and verification-tagged
Who we found publicly on the record — a snapshot, not a poll of the field. Larger dots are deciders; dashed dots are scan-reported, not yet verified.